New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis

Pulmonary Circulation

Volumn 2, Issue 4, 2012, Pages 434-442

  Nicolls, Mark R ^a   Mizuno, Shiro ^b   Taraseviciene Stewart, Laima ^c   Farkas, Laszlo ^d   Drake, Jennnifer I ^d   Al Husseini, Aysar ^d   Gomez Arroyo, Jose G ^d   Voelkel, Norbert F ^d   Bogaard, Herman Jan ^e  

^a STANFORD UNIVERSITY   (United States)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF COLORADO   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Chronic hypoxia; Pulmonary hypertension; Regulatory T cells; Su5416

Indexed keywords

EID: 84873673503     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.105031     Document Type: Review

References (68)

1. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118:2372-9.
2. Michelakis ED, Wilkins MR, Rabinovitch M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation 2008;118:1486-95.
3. Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54 (1 Suppl):S10-S19.
4. Majka S, Burnham E, Stenmark KR. Cell-based therapies in pulmonary hypertension: Who, what, and when? Am J Physiol Lung Cell Mol Physiol 2011;301:L9-L11.
5. Fadini GP, Avogaro A, Ferraccioli G, Agostini C. Endothelial progenitors in pulmonary hypertension: New pathophysiology and therapeutic implications. Eur Respir J 2010;35:418-25.
6. Macchia A, Marchioli R, Marfisi R, Scarano M, Levantesi G, Tavazzi L, et al. A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-47.
7. Macchia A, Mariani J, Comignani PD, Tognoni G. Clinical Trials Using Vasodilators in Pulmonary Arterial Hypertension: Where Do We Go from Here? Rev Recent Clin Trials, 2011;6:228-34.
8. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
9. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, et al. The Monocrotaline Model of Pulmonary Hypertension In Perspective. Am J Physiol Lung Cell Mol Physiol 2012;302:L363-L369.
10. Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, et al. Strategic Plan for Lung Vascular Research: An NHLBI-ORDR Workshop Report. Am J Respir Crit Care Med 2010;182:1554-62.
11. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J 2001;15:427-38.
12. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
13. Gomez-Arroyo J, Saleem SJ, Mizuno S, Syed AA, Bogaard HJ, Abbate A, et al. A Brief Overview of Mouse Models of Pulmonary Arterial Hypertension: Problems and Prospects. Am J Physiol Lung Cell Mol Physiol 2012;302:L977-91.
14. Sakao S, Tatsumi K. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. Respiration 2011;81:253-61.
15. Ameshima S, Golpon H, Cool CD, Chan D, Vandivier RW, Gardai SJ, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ Res 2003;92:1162-9.
16. Hansmann G, Plouffe BD, Hatch A, von Gise A, Sallmon H, Zamanian RT, et al. Design and validation of an endothelial progenitor cell capture chip and its application in patients with pulmonary arterial hypertension. J Mol Med (Berl) 2011;89:971-83.
17. Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, et al. Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary Hypertension. Circ Res 2011;109:867-79.
18. Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, et al. Altered microRNA Processing in Heritable Pulmonary Arterial Hypertension: An Important Role for Smad-8. Am J Respir Crit Care Med 2011;184:1400-8.
19. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:558-64.
20. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-9.
21. Keskin U, Totan Y, Karadağ R, Erdurmuş M, Aydın B. Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization. Ophthalmic Res 2011;47:13-8.
22. Rasmussen JG, Frøbert O, Pilgaard L, Kastrup J, Simonsen U, Zachar V, et al. Prolonged hypoxic culture and trypsinization increase the pro-angiogenic potential of human adipose tissue-derived stem cells. Cytotherapy 2011;13:318-28.
23. Novitskiy SV, Csiki I, Huang Y, Johnson DH, Harth EM, Carbone DP, et al. Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells. J Thorac Oncol 2010;5:1410-5.
24. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice. Am J Physiol Cell Physiol 2007;293:C419-C428.
25. Shimotake J, Derugin N, Wendland M, Vexler ZS, Ferriero DM. Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke. Stroke 2010;41:343-9.
26. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600-L607.
27. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121:2747-54.
28. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, et al. Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats. Circ Res 2007;100:923-9.
29. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2006;291:L668-L676.
30. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009;120:1951-60.
31. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: A perspective. Eur Respir J 2005;26:1110-8.
32. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, et al. Absence of T Cells Confers Increased Pulmonary Arterial Hypertension and Vascular Remodeling. Am J Respir Crit Care Med 2007;175:1280-9.
33. Miyata M, Sakuma F, Ito M, Ohira H, Sato Y, Kasukawa R. Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration. Int Arch Allergy Immunol 2000;121:246-52.
34. Voelkel NF, Gomez-Arroyo JG, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of Pulmonary Arterial Hypertension and Right Ventricular Failure. Eur Respir J 2012 [In Press].
35. Tamosiuniene R, Nicolls MR. Regulatory T cells and pulmonary hypertension. Trends Cardiovasc Med 2011;21:166-71.
36. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008;205:361-72.
37. Lee KS, Kim SR, Park HS, Park SJ, Min KH, Lee KY, et al. A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-kappaB and hypoxia-inducible factor-1alpha. Exp Mol Med 2007;39:756-68.
38. Mizuno S, Farkas L, Alhussaini A, Farkas D, Gomez-Arroyo J, Kraskauskas D, et al. Severe Pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. Am J Respir Cell Mol Biol 2012 [In Press].
39. Farkas L, et al. Vegf receptor inhibition in experimental lung fibrosis results in severe angioproliferative pulmonary hypertension and increased fibrogenic activity Am J Respir Crit Care Med 2010;181:A6315.
40. Farkas L, Farkas D, Ask K, Möller A, Gauldie J, Margetts P, et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009;119:1298-311.
41. Farkas L, Farkas D, Kraskauskas D, Gauldie J, Kolb M, Voelkel N. Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis. Eur Respir J 2011;38:594s.
42. Voelkel NF, Cool CD. The Pathobiology of the Complex Vascular Lesions in Severe Pulmonary Hypertension-Angiogenesis and Cancer, in Pulmonary Hypertension: The Present and Future. N.V. Ed, Editor. Connecticut: People’s Medical Publishing House Shelton; 2011. p. 87-103.
43. Voelkel NF, Cool C, Taraceviene-Stewart L, Geraci MW, Yeager M, Bull T, et al. Janus face of vascular endothelial growth factor: The obligatory survival factor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med 2002;30 (5 Suppl):S251-S256.
44. dela Paz NG, Walshe TE, Leach LL, Saint-Geniez M, D’Amore PA. Role of shear-stress-induced VEGF expression in endothelial cell survival. J Cell Sci 2012;125:831-43.
45. Stevens T, Kasper M, Cool C, Voelkel NF. Pulmonary circulation and pulmonary hypertension. In: Endothelial Cells in Health and Disease. Editor: Aird WC. Informa Healthcare 2005: 417-438.
46. Montani D, Bergot E, Günther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125:2128-37.
47. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. Faseb J 2005;19:1178-80.
48. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006;12:6808-16.
49. Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: What does the future hold? Future Oncol 2012;8:403-14.
50. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14.
51. Ebos JM, Kerbel RS. Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21.
52. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J 1999;18:882-92.
53. Hall H, Hubbell JA. Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating alphavbeta3-integrin and activating VEGF-R2. Microvasc Res 2004;68:169-78.
54. Al Husseini A, Bagnato G, Farkas L, Gomez-Arroyo J, Farkas D, Mizuno S, et al. Thyroid hormone is highly permissive in angioproliferative pulmonary arterial hypertension in rats. Eur Respir J 2012 [In Press].
55. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiters G, et al. Copper-dependence of angioproliferation in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2012;46:582-91.
56. Sweeney L, Chhatwani L. Endocrine aspects of pulmonary hypertension, in Pulmonary hypertension: Present and future. Shelton, Connecticut: People’s Medical Publishing House; 2011. p. 239-49.
57. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol 2010;6:431-43.
58. Davis FB, Mousa SA, O’Connor L, Mohamed S, Lin HY, Cao HJ, et al. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 2004;94:1500-6.
59. Eliceiri BP, Klemke R, Strömblad S, Cheresh DA. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255-63.
60. Finley SD, Popel AS. Predicting the Effects of Anti-angiogenic Agents Targeting Specific VEGF Isoforms. AAPS J 2012;14:500-9.
61. Benedito R, Rocha SF, Woeste M, Zamykal M, Radtke F, Casanovas O, et al. Notch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signalling. Nature 2012;484:110-4.
62. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 2004;103:3883-9.
63. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC. VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One 2011;6:e25668.
64. Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, et al. VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node Lymphatics. Cell Reports 2012;1:191-9.
65. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 2012; 109:2784-9.
66. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 1997;151:1019-25.
67. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:1239-47.
68. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007;110:624-31.